Ono Pharmaceutical CoTSE:4528 +1.58%88 EBITDA Margin % is 11.80% as of Mar. 2026, which is 64% below its 10-year median of 33.08. GuruFocus rates TSE:4528 with a GF Score™ of 88/100 and a GF Value™ of 円2,255.53 (Fairly Valued). The stock has 2 warning signs investors should review. Among 955 Drug Manufacturers companies, Ono Pharmaceutical Co ranks better than 79.9% on this metric.
Ono Pharmaceutical Co (TSE:4528) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Ono Pharmaceutical Co EBITDA Margin % Related Terms
Ono Pharmaceutical Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Ono Pharmaceutical Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4528 vs LLY, JNJ, ABBV: EBITDA Margin % Comparison
For the Drug Manufacturers - General subindustry, Ono Pharmaceutical Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ono Pharmaceutical Co EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ono Pharmaceutical Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Ono Pharmaceutical Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ono Pharmaceutical Co (TSE:4528) has a EBITDA Margin % of 11.80% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Ono Pharmaceutical Co and its competitors. This is 64% below median its historical median of 33.08. Over the past decade, Ono Pharmaceutical Co's EBITDA Margin % has ranged from 18.80 to 37.78. According to the industry distribution chart, Ono Pharmaceutical Co ranks #192 out of 955 companies in the Drug Manufacturers industry, placing it in the top 20.1%.
Is Ono Pharmaceutical Co's EBITDA Margin % too high?
Ono Pharmaceutical Co's current EBITDA Margin % of 11.80% is 64% below median its 10-year median of 33.08. Over the past 10 years, this metric has ranged from a low of 18.80 to a high of 37.78. The Drug Manufacturers industry median EBITDA Margin % is 12.44. Ono Pharmaceutical Co's value of 11.80% is 5.1% below this industry median. Based on the distribution chart, Ono Pharmaceutical Co ranks #192 out of 955 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Ono Pharmaceutical Co has a GF Score™ of 88/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ono Pharmaceutical Co's EBITDA Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Ono Pharmaceutical Co ranks #192 out of 955 companies for EBITDA Margin %. This places Ono Pharmaceutical Co in the top 20% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.44. Ono Pharmaceutical Co's value of 11.80% is 5.1% below this benchmark. Historically, Ono Pharmaceutical Co's own EBITDA Margin % has ranged from 18.80 to 37.78 over the past decade. While the company's 10-year median is 33.08 vs. the industry median of 12.44, Ono Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.44, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ono Pharmaceutical Co's current EBITDA Margin % of 11.80% is 5.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Ono Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ono Pharmaceutical Co's current EBITDA Margin % is 11.80%, which is 64% below median its own 10-year median of 33.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ono Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Ono Pharmaceutical Co (TSE:4528) is currently considered Fairly Valued. The stock's GF Value™ is 円2,255.53, compared to a current price of 円2,377.50 — trading 5.4% above its estimated fair value. The current EBITDA Margin % is 11.80%, which is 64% below median its 10-year median of 33.08 and 5.1% below the Drug Manufacturers industry median of 12.44. Ono Pharmaceutical Co's overall GF Score™ is 88/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Ono Pharmaceutical Co (TSE:4528), the current EBITDA Margin % is 11.80% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ono Pharmaceutical Co (TSE:4528) Overvalued in 2026?
Based on GuruFocus' analysis, Ono Pharmaceutical Co stock appears to be overvalued.
The current stock price of 円2,377.50 is trading 5.4% above its estimated GF Value™ of 円2,255.53.
GuruFocus considers Ono Pharmaceutical Co to be Fairly Valued.
Key valuation signals for TSE:4528:
EBITDA Margin %: 11.80% (64% below median its 10-year median of 33.08)
GF Value™: 円2,255.53 vs. price of 円2,377.50 (5.4% above fair value)
Industry Position: 5.1% below the Drug Manufacturers median (#192 of 955)
No single metric tells the full story. See the TSE:4528 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ono Pharmaceutical Co Ltd is a drug manufacturer with a focus on drug discovery in areas of unmet medical needs. The vast majority of the company's revenue is derived from its circulatory and respiratory drugs, followed by its metabolic drugs and vitamins. The company also reports revenue derived from royalties. The bulk of the company's sales is generated in Japan, followed by the rest of Asia and Europe.
88GF Score
Get the complete analysis for TSE:4528
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4528 has been successfully added to your 
